Badakva G.V., Yusufov A.G., Bogdanov D.A., Kotov S.V.
Drug and behavioral therapy in the treatment of lower urinary tract symptoms that persist after surgical treatment of benign prostatic hyperplasia
|
№1 / 2025
|
Kasyan G.R., Khodyreva L.A., Grigoryan B.L., Dyakov V.V.
Practical use of Adenoprosin® in combination therapy in men with lower urinary tract symptoms
|
№1 / 2024
|
M.I. Kogan, N.V. Vorobyeva, I.I. Belousov
Prevalence and severity of lower urinary tract symptoms during the first pregnancy in healthy women
|
№5 / 2023
|
S.P. Abdullaev, M.N. Shatokhin, O.V. Teodorovich, D.A. Sychev
Molecular genetic predictors of the efficacy and safety of tamsulosin therapy
|
№6 / 2022
|
D.Yu. Pushkar, O.B. Loran, A.N. Bernikov
The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)
|
№6 / 2022
|
A.G. Martov, A.S. Dukhanin, A.N. Bernikov
Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience
|
№3 / 2022
|
B.A. Neymark, A.I. Neymark, Ya.V. Yakovets, N.A. Nozdrachev, Kh.S. Ibishev, I.V. Kuzmin
Management of lower urinary tract symptoms in patients with benign prostatic hyperplasia during COVID-19. results of an all-russian observational study “ATLANT”
|
№1 / 2022
|
I.A. Shaderkin, G.S. Lebedev, V.A. Shaderkina, D.M. Monakov,
L.G. Spivak, Z.K. Gadzhieva, M.A. Gazimiev
Outpatient urodynamic monitoring in patients with BPH: world and russian experience
|
№6 / 2021
|
A.V. Kuzmenko, V.V. Kuzmenko, T.A. Gyaurgiev
Modern possibilities of therapy of a urological patient with concomitant diseases of the cardiovascular system
|
№6 / 2021
|
D.V. Ergakov, A.G. Martov
New approaches to combined therapy of irritative symptoms in patients with benign prostatic hyperplasia
|
№2 / 2021
|
A.V. Sivkov, V.I. Kirpatovskyi
Iscussion on the use of hexane extract of Serenoa repens for combination therapy in patients with LUTS/BPH
|
№1 / 2021
|
D.V. Ergakov, A.G. Martov
Paradigm shift in combination therapy during the COVID-19 pandemic
|
№1 / 2021
|